NASDAQ:IDXG - Nasdaq -
3.92
+0.02 (+0.51%)
The current stock price of IDXG is 3.92 null. In the past month the price decreased by -11.51%. In the past year, price decreased by -52.31%.
Interpace Biosciences Inc. is enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services include molecular diagnostic tests, bioinformatics, and pathology services. Pharma services provide pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. Interpace Biosciences Inc., formerly known as INTERPACE DIAGN, is based in PARSIPPANY, NJ.
Interpace Diag Group
MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY
PARSIPPANY NJ 07054
CEO: Jack E. Stover
Phone: 855-776-6419
The current stock price of IDXG is 3.92 null. The price increased by 0.51% in the last trading session.
The exchange symbol of Interpace Diag Group is IDXG and it is listed on the Nasdaq exchange.
IDXG stock is listed on the Nasdaq exchange.
Interpace Diag Group (IDXG) has a market capitalization of 16.09M null. This makes IDXG a Nano Cap stock.
Interpace Diag Group (IDXG) has a support level at 3.91 and a resistance level at 5.78. Check the full technical report for a detailed analysis of IDXG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IDXG does not pay a dividend.
Interpace Diag Group (IDXG) will report earnings on 2022-05-09.
Interpace Diag Group (IDXG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.94).
The outstanding short interest for Interpace Diag Group (IDXG) is 0.01% of its float. Check the ownership tab for more information on the IDXG short interest.
ChartMill assigns a technical rating of 3 / 10 to IDXG. When comparing the yearly performance of all stocks, IDXG is a bad performer in the overall market: 95.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IDXG. IDXG may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months IDXG reported a non-GAAP Earnings per Share(EPS) of -4.9399999999999995. The EPS decreased by -25.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -106.8% | ||
ROA | -56.81% | ||
ROE | N/A | ||
Debt/Equity | -0.16 |
ChartMill assigns a Buy % Consensus number of 100% to IDXG. The Buy consensus is the average rating of analysts ratings from 2 analysts.